Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Ramssol Group Bhd
KLSE:RAMSSOL
|
MY |
|
N
|
Nishimatsu Construction Co Ltd
TSE:1820
|
JP |
Orchestra Biomed Holdings Inc
Inventory
Orchestra Biomed Holdings Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
Inventory
$310k
|
CAGR 3-Years
3%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Inventory
$2.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Inventory
$1.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
7%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Inventory
$5.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Inventory
$6.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Inventory
$1.8B
|
CAGR 3-Years
27%
|
CAGR 5-Years
25%
|
CAGR 10-Years
27%
|
|
Orchestra Biomed Holdings Inc
Glance View
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
See Also
What is Orchestra Biomed Holdings Inc's Inventory?
Inventory
310k
USD
Based on the financial report for Dec 31, 2025, Orchestra Biomed Holdings Inc's Inventory amounts to 310k USD.
What is Orchestra Biomed Holdings Inc's Inventory growth rate?
Inventory CAGR 5Y
35%
Over the last year, the Inventory growth was 79%. The average annual Inventory growth rates for Orchestra Biomed Holdings Inc have been 3% over the past three years , 35% over the past five years .
